within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AA01_Ondansetron;
model Ondansetron_1 
   extends Pharmacolibrary.Drugs.ATC.A.A04AA01_1;

  annotation(Documentation(
    info ="<html><body><p>Ondansetron is a selective serotonin 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiotherapy, and surgery. It is approved and widely used internationally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following intravenous administration in healthy adults; parameters reflect standard IV dosing.</p><h4>References</h4><ol><li><p>Sotelo, CK, et al., &amp; Zersen, KM (2022). Pharmacokinetics and anti-nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea. <i>Journal of veterinary pharmacology and therapeutics</i> 45(6) 508–515. DOI:<a href=&quot;https://doi.org/10.1111/jvp.13087&quot;>10.1111/jvp.13087</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35899472/&quot;>https://pubmed.ncbi.nlm.nih.gov/35899472</a></p></li><li><p>Quimby, JM, et al., &amp; Gustafson, DL (2014). Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats. <i>Journal of veterinary pharmacology and therapeutics</i> 37(4) 348–353. DOI:<a href=&quot;https://doi.org/10.1111/jvp.12094&quot;>10.1111/jvp.12094</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24330064/&quot;>https://pubmed.ncbi.nlm.nih.gov/24330064</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Ondansetron_1;
